Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Wnt/β-catenin Pathway Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BCL9 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BCL9 Recombinant Protein (Full-Length & β-catenin Binding Domain). High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. Ideal for PPI assays. | View BCL9 Products |
| Gene Delivery | BCL9 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and overexpression studies. | View BCL9 Products |
| Benchmark Control | Anti-BCL9 Detection Antibodies. For WB/IHC validation. | View BCL9 Products |
| Validator | BCL9 siRNA Set. For knockdown verification and specificity checks. | View BCL9 Products |
| Resistance Mutant | BCL9 Mutant Variants (R35A, W39A, etc.). Binding-defective controls and drug resistance models. | View BCL9 Products |
| Paralog Selectivity | BCL9L (BCL9-Like) Recombinant Protein. For off-target screening against close homolog. | View BCL9L Products |
| Binding Partner | CTNNB1 (β-catenin) Recombinant Protein. For PPI assays and competition studies. | View CTNNB1 Products |
| Pathway Partner | TCF7L2 (TCF4). Transcriptional partner in Wnt signaling complex. | View TCF7L2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PPI Disruption (BCL9-β-catenin) | Isolated β-catenin binding domains with verified folding (>95% purity) for SPR/BLI kinetics. |
| Paralog Selectivity (BCL9 vs BCL9L) | Strictly sequence-verified ortholog proteins; distinct domain architectures available for specificity profiling. |
| Resistance Mutation Screening | Site-directed mutants (R35A, W39A) available for mechanism validation and drug resistance modeling. |
| Intracellular Target Validation | Lentivirus-mediated stable cell lines to monitor endogenous Wnt signaling suppression. |
| False Positives in Screening | Validated siRNA sets included to confirm true on-target degradation or inhibition. |
Live BCL9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BCL9 therapeutics is intensifying, with major players shifting focus from traditional Wnt pathway inhibitors to direct BCL9/β-catenin PPI disruptors. As an intracellular scaffolding protein, BCL9 has historically been deemed "undruggable." However, as first-generation stapled peptides and small molecules advance, the next wave of R&D is heavily targeting targeted protein degradation (PROTACs) and molecular glues to completely eradicate BCL9-mediated oncogene transcription in solid tumors. Current development focuses primarily on colorectal cancer, hepatocellular carcinoma, and hematological malignancies where Wnt/β-catenin signaling drives tumor progression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Academic consortia, Emerging biotech | Colorectal Cancer, Multiple Myeloma, Refractory Cancers | Full-length BCL9 Protein for Ternary Complex Formation & Degradation Assays |
| Stapled Peptides | Preclinical biotech, Early Stage Biotechs | Colorectal Cancer, HCC, Solid Tumors | β-catenin Binding Domain for Competition SPR; PPI Assay with ultra-pure CTNNB1 & BCL9 fragments |
| Small Molecule PPI Inhibitor | Pharma discovery, Academic/Pharma Consortia | Wnt-driven Solid Tumors, Hematological Malignancies | Paralog Selectivity Panel (BCL9 vs BCL9L); Homolog panels & mutant variants |